Previous Close | 3.00 |
Open | 11.50 |
Bid | 10.50 |
Ask | 15.40 |
Strike | 160.00 |
Expire Date | 2024-05-17 |
Day's Range | 11.50 - 15.20 |
Contract Range | N/A |
Volume | |
Open Interest | 9 |
SAN MATEO, Calif., May 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28 abstracts accepted at EHA2024, with four scheduled for oral presentations.
A week ago, BeiGene, Ltd. ( NASDAQ:BGNE ) came out with a strong set of quarterly numbers that could potentially lead...
BeiGene ( NASDAQ:BGNE ) First Quarter 2024 Results Key Financial Results Revenue: US$751.7m (up 68% from 1Q 2023). Net...